Literature DB >> 33637354

Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC State-of-the-Art Review.

Salva R Yurista1, Cher-Rin Chong2, Juan J Badimon3, Daniel P Kelly4, Rudolf A de Boer5, B Daan Westenbrink6.   

Abstract

Metabolic perturbations underlie a variety of cardiovascular disease states; yet, metabolic interventions to prevent or treat these disorders are sparse. Ketones carry a negative clinical stigma as they are involved in diabetic ketoacidosis. However, evidence from both experimental and clinical research has uncovered a protective role for ketones in cardiovascular disease. Although ketones may provide supplemental fuel for the energy-starved heart, their cardiovascular effects appear to extend far beyond cardiac energetics. Indeed, ketone bodies have been shown to influence a variety of cellular processes including gene transcription, inflammation and oxidative stress, endothelial function, cardiac remodeling, and cardiovascular risk factors. This paper reviews the bioenergetic and pleiotropic effects of ketone bodies that could potentially contribute to its cardiovascular benefits based on evidence from animal and human studies.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; heart failure; ketones; pleiotropic effects

Mesh:

Substances:

Year:  2021        PMID: 33637354     DOI: 10.1016/j.jacc.2020.12.065

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  25 in total

Review 1.  Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer.

Authors:  Anja Karlstaedt; Javid Moslehi; Rudolf A de Boer
Journal:  Nat Rev Cardiol       Date:  2022-04-19       Impact factor: 32.419

2.  Acute Echocardiographic Effects of Exogenous Ketone Administration in Healthy Participants.

Authors:  Senthil Selvaraj; Ray Hu; Mahesh K Vidula; Supritha Dugyala; Ann Tierney; Bonnie Ky; Kenneth B Margulies; Svati H Shah; Daniel P Kelly; Paco E Bravo
Journal:  J Am Soc Echocardiogr       Date:  2021-11-17       Impact factor: 5.251

3.  Boosting mitochondrial metabolism with dietary supplements in heart failure.

Authors:  Kevin D O'Brien; Rong Tian
Journal:  Nat Rev Cardiol       Date:  2021-10       Impact factor: 49.421

4.  Circadian clock controls rhythms in ketogenesis by interfering with PPARα transcriptional network.

Authors:  Volha Mezhnina; Oghogho P Ebeigbe; Nikkhil Velingkaar; Allan Poe; Yana Sandlers; Roman V Kondratov
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-26       Impact factor: 12.779

5.  First Report Of 50-Day Continuous Fasting in Symptomatic Multivessel Coronary Artery Disease and Heart Failure: Cardioprotection Through Natural Ketosis.

Authors:  Saivaroon Gajagowni; Tushar Tarun; Smrita Dorairajan; Anand Chockalingam
Journal:  Mo Med       Date:  2022 May-Jun

6.  Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.

Authors:  Mikhail N Kosiborod; Svati H Shah; Senthil Selvaraj; Zhuxuan Fu; Philip Jones; Lydia C Kwee; Sheryl L Windsor; Olga Ilkayeva; Christopher B Newgard; Kenneth B Margulies; Mansoor Husain; Silvio E Inzucchi; Darren K McGuire; Bertram Pitt; Benjamin M Scirica; David E Lanfear; Michael E Nassif; Ali Javaheri; Robert J Mentz
Journal:  Circulation       Date:  2022-05-23       Impact factor: 39.918

7.  Metabolic Strategies in Healthcare: A New Era.

Authors:  Matthew Cl Phillips
Journal:  Aging Dis       Date:  2022-06-01       Impact factor: 9.968

8.  MALAT1 regulates hypertrophy of cardiomyocytes by modulating the miR-181a/HMGB2 pathway.

Authors:  Feng Chen; Wenfeng Li; Dandan Zhang; Youlin Fu; Wenjin Yuan; Gang Luo; Fuwei Liu; Jun Luo
Journal:  Eur J Histochem       Date:  2022-06-21       Impact factor: 1.966

Review 9.  β-Hydroxybutyrate in Cardiovascular Diseases : A Minor Metabolite of Great Expectations.

Authors:  Shao Wei; Liu Binbin; Wu Yuan; Zhang Zhong; Lin Donghai; Huang Caihua
Journal:  Front Mol Biosci       Date:  2022-06-13

10.  ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca2+ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKIIδ.

Authors:  Mario G Pavez-Giani; Pablo I Sánchez-Aguilera; Nils Bomer; Shigeki Miyamoto; Harmen G Booij; Paula Giraldo; Silke U Oberdorf-Maass; Kirsten T Nijholt; Salva R Yurista; Hendrik Milting; Peter van der Meer; Rudolf A de Boer; Joan Heller Brown; Herman W H Sillje; B Daan Westenbrink
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.